Jump Financial LLC Takes $4.09 Million Position in GeneDx Holdings Corp. $WGS

Key Points

• Jump Financial LLC acquired 46,215 shares of GeneDx Holdings Corp. in the 1st quarter, valued at approximately $4,093,000, increasing its stake to about 0.16% of the company.
• A significant insider transaction occurred as CFO Kevin Feeley sold 388 shares at an average price of $105.31, while Director Casdin Capital, LLC sold 500,000 shares for $60,450,000.
• GeneDx’s stock is currently experiencing volatility, trading down 5.3%, and has had a significant increase in share value of 2,700% this year, with competing price targets from various analysts between $80.00 and $135.00.

Jump Financial LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 46,215 shares of the company's stock, valued at approximately $4,093,000. Jump Financial LLC owned approximately 0.16% of GeneDx at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. purchased a new position in shares of GeneDx in the first quarter valued at approximately $44,614,000. Wellington Management Group LLP lifted its position in shares of GeneDx by 202.3% in the first quarter. Wellington Management Group LLP now owns 425,647 shares of the company's stock valued at $37,697,000 after acquiring an additional 284,855 shares in the last quarter. Northern Trust Corp lifted its position in shares of GeneDx by 3.1% in the first quarter. Northern Trust Corp now owns 185,189 shares of the company's stock valued at $16,401,000 after acquiring an additional 5,538 shares in the last quarter. Algert Global LLC lifted its position in shares of GeneDx by 11.2% in the first quarter. Algert Global LLC now owns 47,726 shares of the company's stock valued at $4,227,000 after acquiring an additional 4,800 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of GeneDx by 25.8% in the first quarter. Raymond James Financial Inc. now owns 333,376 shares of the company's stock valued at $29,525,000 after acquiring an additional 68,331 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

Insiders Place Their Bets

In other news, CEO Katherine Stueland sold 2,154 shares of GeneDx stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total value of $226,837.74. Following the completion of the sale, the chief executive officer directly owned 3,440 shares of the company's stock, valued at approximately $362,266.40. The trade was a 38.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the completion of the sale, the director directly owned 3,007,164 shares of the company's stock, valued at $363,566,127.60. The trade was a 14.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 561,633 shares of company stock worth $67,530,714 in the last three months. 29.60% of the stock is owned by insiders.

GeneDx Trading Up 0.4%

WGS stock traded up $0.49 during midday trading on Friday, hitting $129.49. 441,270 shares of the company's stock were exchanged, compared to its average volume of 748,496. The business has a 50-day simple moving average of $100.03 and a two-hundred day simple moving average of $89.50. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $3.72 billion, a PE ratio of 2,589.80 and a beta of 2.02. GeneDx Holdings Corp. has a 1-year low of $28.86 and a 1-year high of $130.91.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.40. The company had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analyst Ratings Changes

WGS has been the subject of several recent research reports. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler set a $120.00 price target on GeneDx and gave the company an "overweight" rating in a report on Monday, August 4th. Wells Fargo & Company increased their price target on GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Guggenheim reaffirmed a "buy" rating and issued a $115.00 price target (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Finally, Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Friday, May 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, GeneDx has a consensus rating of "Moderate Buy" and a consensus target price of $101.63.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.